# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN-TD
- Date: 1984-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing care for memory loss and getting lost, with his care partner: cognitive testing, reversible causes, medicines, diabetes and blood pressure, driving and firearm safety. **S**

## Objective

White blood cells: 6.4 10*3/uL; Hemoglobin: 14.1 g/dL; Platelets: 231 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1979): 85 mL/min/1.73 m²; Glucose: 126 mg/dL; Hemoglobin A1c: 6.4% (high); Vitamin B12: 352 pg/mL; TSH: 1.9 mIU/L; Urine albumin-to-creatinine ratio: 14 mg/g; MoCA: 18; PHQ-9: 4. All results are synthetic.

BP 132/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 77 kg; BMI 23.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found; Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea; Hypertension, controlled on lisinopril. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Continued without change: Glipizide 5 mg oral tablet, one tablet before breakfast **S**
- Continued without change: Lisinopril 20 mg oral tablet, one tablet daily **S**
- Continued without change: Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Stopped: Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter **S**

## Plan

- Dementia work-up under the Alzheimer's Association guideline: history from him and his care partner, MoCA, function, depression screening, first-tier blood tests (blood count, metabolic panel, B12, TSH), a review of medicines for anticholinergic and sedating drugs, a sleep apnea screen, and brain MRI. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026) **S**
- Cognitive neurology consultation at the memory clinic to stage the dementia, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, choose biomarker testing, and decide anti-amyloid eligibility. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021) **S**
- Stop diphenhydramine, a strongly anticholinergic sleep aid; sleep habits and morning light instead. Guideline: American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023) **S**
- Driving: no driving until the evaluation is complete, with his care partner driving; firearm: unloaded and locked, with the key held by his care partner, until a decision with him. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Practice Parameter update: Evaluation and management of driving risk in dementia (2010) **S**
- Blood pressure under 130/80 mmHg on lisinopril, with potassium and creatinine checks. Guideline: CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
- Advance care planning while he can take part fully: a health care agent and his values, at the preventive visit. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024) **S**
- Exercise, social activity and diabetes and blood pressure control as the brain-health measures with the most support. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
